As Pfizer Inc. (PFE) and Eli Lilly & Co. (LLY) recently shared contrasting updates regarding their investigational oral GLP-1 drugs - Pfizer with a setback and Lilly with promising results - Lexaria Bioscience Corp. (LEXX) believes its proprietary DehydraTECH drug delivery technology could be of value to both companies.
On April 14, 2025, Pfizer announced the termination of its development program for Danuglipron as a once-daily oral GLP-1 therapy after a trial participant experienced a liver injury potentially linked to the drug. This follows an earlier setback in December 2023, when the company halted development of a twice-daily version of the same drug due to adverse side effects.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com